May 7, 2025 updated by: CytoDyn, Inc. A Phase Two
Post# of 155214
(Total Views: 476)
Posted On: 07/02/2025 7:58:19 PM
May 7, 2025 updated by: CytoDyn, Inc.
A Phase Two Study Evaluating Two Doses of Leronlimab (Pro 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCR)
Source read in full
https://ichgcp.net/clinical-trials-registry/NCT06699836
A Phase Two Study Evaluating Two Doses of Leronlimab (Pro 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCR)
Source read in full
https://ichgcp.net/clinical-trials-registry/NCT06699836
(2)
(0)